Ventyx Biosciences to be Acquired by Eli Lilly for $14.00 Per Share in Cash

summarizeSummary

Ventyx Biosciences, Inc. announced a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per share in cash, a significant premium over its current stock price.

check_boxKey Events

• Definitive Merger Agreement

  Ventyx Biosciences, Inc. has entered into an Agreement and Plan of Merger with Eli Lilly and Company, under which Eli Lilly will acquire Ventyx Biosciences.

• Acquisition Price Set

  Each share of common stock will be converted into the right to receive $14.00 per share in cash, without interest, representing a premium over the current stock price of $13.73.

• Shareholder Support Agreement

  Somasundaram Subramaniam, a significant beneficial owner (5.8% of class), has entered into a Voting and Support Agreement, committing to vote in favor of the merger.

• Equity Awards Treatment

  Outstanding stock options and restricted stock units will be cancelled and converted into a cash payment based on the $14.00 merger consideration, less exercise price for options.

auto_awesomeAnalysis

Ventyx Biosciences, Inc. has entered into a definitive merger agreement to be acquired by Eli Lilly and Company for $14.00 per share in cash. This represents a premium over the current trading price and signifies a complete acquisition of the company. A major shareholder, Somasundaram Subramaniam, has signed a voting and support agreement, indicating strong insider backing for the transaction. This event fundamentally alters the investment thesis for Ventyx Biosciences, as the company will become a wholly-owned subsidiary of Eli Lilly, providing a clear exit for shareholders at the agreed-upon cash price.